SOUTH SAN FRANCISCO, CA - (HSMN NewsFeed) - Theravance, Inc. (NASDAQ:THRX ) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the telavancin New Drug Application (NDA) for the treatment …
Biopharmaceuticals, FDA
Theravance, Telavancin, nosocomial pneumonia, nosocomial, antibiotic

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia”
Leave a Comment